Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by programmed cell death-1 (PD-1) and its ligand program...

Descripción completa

Detalles Bibliográficos
Autores principales: Faiena, Izak, Cummings, Amy L, Crosetti, Anna M, Pantuck, Allan J, Chamie, Karim, Drakaki, Alexandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789049/
https://www.ncbi.nlm.nih.gov/pubmed/29416316
http://dx.doi.org/10.2147/DDDT.S141491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789049/
https://www.ncbi.nlm.nih.gov/pubmed/29416316
http://dx.doi.org/10.2147/DDDT.S141491

Ejemplares similares